z-logo
open-access-imgOpen Access
Detection of Drug‐Resistant Minority Variants of HIV‐1 During Virologic Failure of Indinavir, Lamivudine, and Zidovudine
Author(s) -
Carrie Dykes,
Joe Najjar,
Ronald J. Bosch,
Michael Wantman,
Manohar R. Furtado,
Stephen A. Hart,
Scott M. Hammer,
Lisa M. Demeter
Publication year - 2004
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/382033
Subject(s) - indinavir , zidovudine , lamivudine , virology , sida , context (archaeology) , medicine , biology , virus , viral disease , hepatitis b virus , paleontology
We evaluated zidovudine-experienced patients for whom treatment with indinavir, lamivudine, and zidovudine failed, for indinavir-resistant minority variants. Of 10 patients with plasma human immunodeficiency virus type 1 RNA suppression and subsequent rebound, 6 without primary indinavir-resistance mutations underwent clonal analysis. One had evidence of V82A in 9 of 30 clones at week 24, with no increase at week 40. The dominant week-40 82V-M184V clones had changes at protease codons 62-64, compared with all clones at week 24 and minority clones at week 40. Resistance to indinavir can emerge during treatment failure in nucleoside-experienced patients but may be missed by routine sequence analysis. Selection for indinavir-resistant variants on treatment with indinavir, lamivudine, and zidovudine may occur slowly, depending on the genetic context in which they arise.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom